LY 3108743

Drug Profile

LY 3108743

Alternative Names: LY-3108743

Latest Information Update: 09 Sep 2014

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 30 Apr 2014 Eli Lilly completes a phase I trial in Type-2 diabetes mellitus in Singapore (NCT01995656)
  • 31 Dec 2013 Phase-I clinical trials in Type-2 diabetes mellitus in Singapore (PO)
  • 20 Nov 2013 Preclinical trials in Type-2 diabetes mellitus in USA (PO, liquid & PO, capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top